Home > Insider Trading > Filing (0001181431-10-052254)

Filing Details

Accession Number:: 0001181431-10-052254
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-10-27 17:48:08
Reporting Period:: 2010-10-27

Filing Date:: 2010-10-27
Accepted Time:: 2010-10-27 17:48:08
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1338042	Aegerion Pharmaceuticals Inc.	AEGR	Pharmaceutical Preparations (2834)	202960116

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1341637	Alison Kiley	One Embarcadero Center Suite 3700 San Francisco CA 94111		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-10-27	1,186,064	$0.00	1,186,064	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2010-10-27	414,388	$0.00	1,600,452	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2010-10-27	764,310	$7.60	2,364,762	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2010-10-27	315,789	$9.50	2,860,551	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2010-10-27	3,064,681	$0.00	1,186,064	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2010-10-27	679,018	$0.00	414,388	$0.00
Common Stock	Senior Subordinated Convertible Promissory Notes	Acquisiton	2010-10-21	0	$0.00	764,310	$7.60
Common Stock	Senior Subordinated Convertible Promissory Notes	Disposition	2010-10-27	0	$0.00	764,310	$7.60

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
	No	4	C	Indirect
	No	4	C	Indirect
2011-12-31	No	4	A	Indirect
2011-12-31	No	4	C	Indirect

Footnotes

Upon the closing of the Issuer's initial public offering on October 27, 2010, each share of Series A Convertible Preferred Stock (the "Series A Shares"), plus accrued dividends, automatically converted into shares of common stock of the Issuer in accordance with the terms of the Issuer's Third Amended and Restated Certificate of Incorporation. Each Series A Share converted into 0.38701117412 shares of common stock.
Alta BioPharma Partners III, L.P. ("ABPIII") acquired 1,086,336 shares of common stock upon the conversion of its Series A Shares, Alta BioPharma Partners III GmbH & Co. Beteiligungs KG ("ABPIIIKG") acquired 72,957 shares of common stock upon the conversion of its Series A Shares, and Alta Embarcadero BioPharma Partners III, LLC ("AEBPIII") acquired 26,771 shares of common stock upon the conversion of its Series A Shares.
The Reporting Person is a member of Alta BioPharma Management III, LLC ("ABMIII"), which is the general partner of ABPIII and the managing limited partner of ABPIIIKG. She may be deemed to share investment power over the securities of the Issuer held by ABPIII, ABPIIIKG and AEBPIII with the directors of ABMIII and managers of AEBPIII but disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein.
Upon the closing of the Issuer's initial public offering on October 27, 2010, each share of Series B Convertible Preferred Stock (the "Series B Shares"), plus accrued dividends, automatically converted into shares of common stock of the Issuer in accordance with the terms of the Issuer's Third Amended and Restated Certificate of Incorporation. Each Series B Share converted into 0.61027657931 basis of common stock.
ABPIII acquired 379,545 shares of common stock upon the conversion of its Series B Shares, ABPIIIKG acquired 25,490 shares of common stock upon the conversion of its Series B Shares, and AEBPIII acquired 9,353 shares of common stock upon the conversion of its Series B Shares.
ABPIII acquired 700,050 shares of common stock upon the conversion of its Convertible Notes, ABPIIIKG acquired 47,010 shares of common stock upon the conversion of its Convertible Notes, and AEBPIII acquired 17,250 shares of common stock upon the conversion of its Convertible Notes.
ABPIII acquired 289,236 shares of common stock in the Issuer's public offering, ABPIIIKG acquired 19,425 shares of common stock in the Issuer's public offering, and AEBPIII acquired 7,128 shares of common stock in the Issuer's public offering. All shares were purchased at the initial public offering price of $9.50 per share.
The Series A Shares were convertible at any time, at the holder's election, and automatically upon consummation of the Issuer's initial public offering and had no expiration date.
The Series B Shares were convertible at any time, at the holder's election, and automatically upon consummation of the Issuer's initial public offering and had no expiration date.
The Convertible Notes were issued on September 2, 2008, December 11, 2008, July 2, 2009, January 28, 2010, June 14, 2010, August 13, 2010 and October 1, 2010. Any outstanding principal amount and accrued but unpaid interest thereon was automatically convertible into shares of capital stock of the Issuer upon the consummation of specified sale transactions involving the securities of the Issuer, including an initial public offering of the Issuer's common stock meeting certain conditions.
ABPIII acquired Convertible Notes with a face amount, including principal and accrued interest, of $5,320,408.54; ABPIIIKG acquired Convertible Notes with a face amount, including principal and accrued interest, of $357,311.91; and AEBPIII acquired Convertible Notes with a face amount, including principal and accrued interest, of $131,117.33.